<DOC>
	<DOCNO>NCT00006171</DOCNO>
	<brief_summary>Background : Kaposi sarcoma ( KS ) cause gammaherpesvirus call Kaposi sarcoma-associated herpesvirus ( KSHV ) , human herpesvirus-8 ( HHV-8 ) . However , infection KSHV sufficient cause KS , HIV infection important cofactor . Treatment HIV potent antiretroviral therapy reduce risk KS , also induce regression patient establish HIV-KS . One mechanism HIV believe contribute KS HIV-induced immunodeficiency lead loss immunologic control KSHV and/or KS . However , mechanism may also contribute . Objectives : One primary objective ass effect initiation potent anti-HIV therapy specific factor possibly link control pathogenesis KS , namely serum viral IL-6 plasma VEGF level , patient KS risk KS virtue infect KSHV/HHV-8 . Another assess effect anti-HIV therapy KSHV infection . Secondary objective assess effect potent antiretroviral therapy establish KS factor relate KS KSHV infection . Eligibility : The principal eligibility factor age 13 , HIV infection , either KS infection KSHV . Exclusion factor include KS require specific therapy , recent corticosteroid therapy , recent cytokine therapy , opportunistic infection require therapy . Design : Patients treat potent antiretroviral therapy . For patient establish KS , effect therapy KS monitor . In addition , variety factor related KS , HIV infection , therapy , KSHV infection monitor . These include HIV viral load , KSHV secretion saliva , CD4 count , serum VEGF level , serum IL-6 level .</brief_summary>
	<brief_title>Effects Potent Antiretroviral Therapy Kaposi Sarcoma</brief_title>
	<detailed_description>Background : Kaposi sarcoma ( KS ) cause gammaherpesvirus call Kaposi sarcoma-associated herpesvirus ( KSHV ) , human herpesvirus-8 ( HHV-8 ) . However , infection KSHV sufficient cause KS , HIV infection important cofactor . Treatment HIV potent antiretroviral therapy reduce risk KS , also induce regression patient establish HIV-KS . One mechanism HIV believe contribute KS HIV-induced immunodeficiency lead loss immunologic control KSHV and/or KS . However , mechanism may also contribute . Objectives : One primary objective ass effect initiation potent anti-HIV therapy specific factor possibly link control pathogenesis KS , namely serum viral IL-6 plasma VEGF level , patient KS risk KS virtue infect KSHV/HHV-8 . Another assess effect anti-HIV therapy KSHV infection . Secondary objective assess effect potent antiretroviral therapy establish KS factor relate KS KSHV infection . Eligibility : The principal eligibility factor age 13 , HIV infection , either KS infection KSHV . Exclusion factor include KS require specific therapy , recent corticosteroid therapy , recent cytokine therapy , opportunistic infection require therapy . Design : Patients treat potent antiretroviral therapy . For patient establish KS , effect therapy KS monitor . In addition , variety factor related KS , HIV infection , therapy , KSHV infection monitor . These include HIV viral load , KSHV secretion saliva , CD4 count , serum VEGF level , serum IL-6 level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 13 year HIV seropositive Either diagnosis Kaposi 's sarcoma and/or HHV8/KSHV seropositive EXCLUSION CRITERIA : Requirement specific antiKS therapy Specific antiKS therapy within 4 week study entry Corticosteroid therapy within 4 week prior initiate study Condition periodically require immune suppressive therapy ( e.g . asthma ) Cytokine therapy within 4 week study entry HIVassociated opportunistic complication require therapy Inability provide inform consent Investigator recommendation antiretroviral therapy best patient interest Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 29, 2012</verification_date>
	<keyword>HHV-8</keyword>
	<keyword>Pathophysiology</keyword>
	<keyword>AIDS</keyword>
	<keyword>Cancer</keyword>
	<keyword>Anti-Retroviral</keyword>
	<keyword>Kaposi 's Sarcoma</keyword>
	<keyword>HIV</keyword>
</DOC>